StockData
Mustang Bio, Inc. logo

Mustang Bio, Inc. (MBIO) company profile

MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.38−0.01 (-2.56%)

Close on Nov 18, 2026Market cap $2.88MP/E –Yield –

About Mustang Bio

Pharmaceutical Preparations, SIC 2834

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on acquiring, developing, and commercializing novel cancer therapies, specifically targeting difficult-to-treat solid tumors. Operating as a majority-controlled subsidiary of Fortress Biotech, Inc., the company concentrates on cell and viral immunotherapies. Its principal pipeline assets include MB-101, an engineered CAR T-cell therapy directed at IL13Rα2, and MB-108, an oncolytic herpes simplex virus. Mustang is also investigating MB-109, a combination regimen evaluating MB-101 and MB-108 for the treatment of malignant brain tumors, including recurrent glioblastoma and high-grade astrocytoma. Because its product candidates remain in clinical evaluation and have not received regulatory marketing approval, the company does not currently serve commercial patients or end-user customers.

The company is headquartered in Waltham, Massachusetts, where it maintains its executive offices. Mustang operates domestically in the United States without commercial sales across geographic markets, employing four full-time personnel as of late 2025.

Summary of the business section of Mustang Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Mustang Bio, Inc.
Founded
2015
Headquarters
Waltham, MA
Address
95 Sawyer Rd, Suite 110 02453
Phone
(781) 652-4500
Employees
4, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, New York, NY

Stock & identifiers

Ticker
MBIO
Exchange
Nasdaq
IPO date
Aug 22, 2017
Shares outstanding
8M, Aug 3, 2026
Public float
$3.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Jan 16, 2025; 1-for-12.75 reverse, May 12, 2023; 1-for-15 reverse, Apr 4, 2023
SEC CIK
1680048
CUSIP
62818Q203
ISIN
US62818Q2030
FIGI
BBG00FXTN420
Share class FIGI
BBG00FXTN439
LEI
5493004W0VC1DPECQ779
EIN
47-3828760

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Manuel Litchman MDPresident, CEO and Interim CFO, Director1,615
Neil HerskowitzDirector145
Adam J. ChillDirector375
David JinDirector286

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$498.04K$487.21K$199.49K$3–
FY2023$514.48K$426.92K$244.28K$23–
FY2022$636.09K$417.05K$347.10K$24–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryOtherTotalvs. prior year
Manuel Litchman, M.D.
President, Chief Executive Officer and Interim Chief Financial Officer
$485.50K$12.54K$498.04K-3%
James Murphy
Former Interim Chief Financial Officer
–$199.49K$199.49K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 4 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?